India's Biocon expects a 50% drop in costs for developing complex biosimilars as the United States has proposed to ease clinical testing for the drugs that make up more than 60% of its revenue, a top executive said on Wednesday.
from NDTV News Search Records Found 1000 https://www.ndtv.com/world-news/us-proposal-could-halve-biocons-biosimilar-development-costs-9630847#publisher=newsstand
Thursday, November 13, 2025
Subscribe to:
Post Comments (Atom)
Hello, my name is Shrinivas N.
No comments:
Post a Comment